Genetic determinants of mammographic density

Breast Cancer Research

Giske Ursin²  Martine Salane¹  Sue A Ingles²  David Van Den Berg²  Leslie Bernstein²  Christopher A Haiman² 

[1] MSW Consulting, Bloomfield Hills, Michigan, USA;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA

关键词: molecular epidemiology;    mammographic density;    genetic susceptibility;    breast cancer;   

Others  :  1118829
DOI  :  10.1186/bcr434

 received in 2002-02-07, accepted in 2002-03-04,  发布年份 2002

【 摘 要 】

Background

Changes in breast density are highly correlated with steroid hormone exposure.

Materials and methods

In a cross-sectional study of 396 Caucasian and African-American women, we evaluated whether polymorphisms in genes involved in steroid hormone biosynthesis and metabolism, CYP17 (T27C), COMT (Val158Met), 17HSDB1 (Ser312Gly) and 3HSDB1 (Asn367Thr), predict mammographic density. We also evaluated whether associations vary by menopausal and hormone replacement therapy status.

Results

We found no strong consistent relationships between polymorphisms in these genes and breast density. African-American women homozygous for the Thr allele of 3HSDB1 had increased density (the absolute difference versus the Asn/Asn genotype was +19.7%; P trend = 0.02), while Caucasian homozygous women had decreased density (-5.1%; P trend = 0.04). Among premenopausal women, carriers of the Ser allele had (not significantly) greater density (versus Gly/Gly genotype: +7.1%; P trend = 0.07). In addition, among current users of hormone replacement therapy, we observed that women with the low-activity Met/Met genotype of COMT had greater breast density (versus the Val/Val genotype: +11.7%; P trend = 0.01).

Conclusion

Additional large studies evaluating these and other candidate breast cancer genes will be required to determine what proportion, if any, of the interindividual differences in breast density are due to underlying genetic variation in genes involved in steroid hormone biosynthesis or metabolism.

【 授权许可】

   
2002 BioMed Central

【 参考文献 】

• [1]Saftlas AF, Szklo M: Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev 1987, 9:146-174.
• [2]Oza AM, Boyd NF: Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993, 15:196-208.
• [3]Boyd NF, Lockwood GA, Martin LJ, Knight JA, Byng JW, Yaffe MJ, Tritchler DL: Mammographic densities and breast cancer risk. Breast Disease 1998, 10:113-126.
• [4]Boyd NF, Byng J, Jong R, Fishell E, Little L, Miller AB, Lockwood G, Tritchler D, Yaffe M: Quantitative classification of mammographic densities and breast cancer risks: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995, 87:670-675.
• [5]Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R: Mammographic features and breast cancer risk: effects with time, age and menopause status. J Natl Cancer Inst 1995, 87:1622-1629.
• [6]Brisson J, Sadowsky NL, Twaddle JA, Morrison AS, Cole P, Merletti F: The relation of mammographic features of the breast to breast cancer risk factors. Am J Epidemiol 1982, 115:438-443.
• [7]Grove JS, Goodman MJ, Gilbert FI, Mi MP: Factors associated with mammographic pattern. Br J Radiol 1985, 58:21-25.
• [8]Ursin G, Parisky TR, Pike MC, Spicer DV: Mammographic density changes during the menstrual cycle. Cancer Epidemiol Biomarkers Prev 2001, 10:141-142.
• [9]Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC: Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994, 86:431-436.
• [10]Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, Pike MC, Spicer DV: The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 1998, 7:43-47.
• [11]Brisson J, Brisson B, Coté G, Maunsell E, Bérubé S, Robert J: Tamoxifen and mammographic densities. Cancer Epidemiol Biomarkers Prev 2000, 9:911-915.
• [12]Greendale GA, Reboussin BA, Sie A, Singh R, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Conner E, for the Postmenopausal Estrogen/Progestin Interventions (PEPI) investigators: Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999, 130:262-269.
• [13]Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L: Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995, 196:433-437.
• [14]Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE: Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 2001, 61:785-789.
• [15]Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ: The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999, 59:1015-1020.
• [16]Lavigne JA, Helzlsouer KJ, Huang H-Y, Strickland PT, Bell DA, Selmin O, Watson MA, Hoffman S, Comstock GW, Yager JD: An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997, 57:5493-5497.
• [17]Marchbanks PA, McDonald JA, Wilson HG, Burnett NM, Daling JR, Bernstein L, Malone KE, Strom BL, Norman SA, Weiss LK, Liff JM, Wingo PA, Burkman RT, Folger SG, Berlin JA, Deapen DM, Ursin G, Coates RJ, Simon MS, Press MF, Spirtas R: The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol,, in press.
• [18]Livak KT: Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999, 14:143-149.
• [19]SAS Institute, IncSAS/STAT User's Guide (version 6, edition 4). Cary: SAS Institute, Inc; 1989.
• [20]Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder BAJ, Easton DF: A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999, 8:843-854.
• [21]Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FS, Henderson BE: Cytochrome P450c17α (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998, 58:585-587.
• [22]Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I: A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 2001, 61:3955-3960.
• [23]Mannermaa A, Peltoketo H, Winqvist R, Ponder BAJ, Kiviniemi H, Easton DF, Poutanen M, Isomaa V, Vihko R: Human familial and sporadic breast cancer: analysis of the coding regions of the 17β-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using single-strand conformation polymorphism assay. Hum Genet 1994, 93:319-324.
• [24]Rhéaume E, Sirois I, Labrie F, Simard J: Codon 367 polymorphism of the human type I 3-hydroxysteroid dehydrogenase/ isomerase gene (HSD3BI). Nucleic Acids Res 1991, 19:6060.
• [25]Van Aswege CH, Purdy RH, Wittliff JL: Binding of 2-hydrox-yestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J Steroid Biochem 1989, 32:485-492.
• [26]Syvanen AC, Tilgmann C, Rinne J, Ulmanen I: Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and Parkinsonian patients in Finland. Pharmacogenetics 1997, 7:65-71.
• [27]Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF: Catechol-O-methyltransferase (COMT)-mediated metabolism of cate-chol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001, 61:6716-6722.
• [28]Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marsha JR, Graham S, Laughlin R, Nemoto T, Kadlubar FF, Ambrosone CB: Genetic polymorphism in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 1998, 58:2107-2110.
• [29]Millikan RC, Pittman GS, Tse CK, Duell E, Newman B, Savitz D, Moorman PG, Biossy RJ, Bell DA: Catehchol-O-methyltransferase and breast cancer risk. Pharmacogenetics 1998, 19:1943-1947.
• [30]Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Kang D, Vainio H, Uusitupa M, Hirvonen A: Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001, 10:635-640.